Changes in immunological and virological parameters in HIV-1 infected subjects following leukapheresis

M. R. Boulassel, G. Spurll, D. Rouleau, C. Tremblay, M. Edwardes, R. P. Sekaly, R. Lalonde, Jean Pierre Routy

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

In order to assess immune responses during HIV-1 therapeutic immunization, a large number of blood mononuclear cells (PBMC) are needed. Clinical tolerance and safety, as well as changes in immunological and virological parameters, were assessed, following leukapheresis in HIV-1 infected subjects with CD4+ cell count > 200 × 106/1. PBMC were collected using a Fenwal CS3000 cell separator in 29 subjects with mean CD4+ cell counts of 503 × 106/1 (range 172-1,119) and viral load of 2.5 log10 copies/ml (range < 1.7-5.4). Twenty-four (83%) subjects were on antiretroviral therapy while 5 (17%) were untreated. The blood volume processed was 7 L over a period of 3 hours. A mean value (± standard error) of 82 ± 26 × 109/1 lymphocytes was collected by a single apheresis in a mean volume of 200 ± 1.8 ml, containing 9.0 ± 1.3 × 109/1 CD4+ and 10.2 ± 1.3 × 109/1 CD8+ cells. The leukapheresis procedures were well tolerated and no immediate or delayed side effects were observed within 90 days of follow-up. No changes from blood pre-leukapheresis values were detected for white blood cells, lymphocytes, monocytes, CD8+, CD34+, naive and memory CD4+ cell counts immediately after, 1 h, 7 days, or within 90 days after leukapheresis. However, absolute CD4+ cell counts and percentage significantly increased from pre-leukapheresis values after 1 h (530 ± 43 vs. 700 ± 75 cell × 106/1; 32.6 ± 1.6 vs. 36.9 ± 1.9%; P < 0.001 for both paired t-tests) before returning to pre-leukapheresis levels on day 7. No significant changes in viral load from pre-leukapheresis levels in treated or untreated subjects were detected at any time points. We conclude that leukapheresis in HIV-1 infected subjects with CD4+ cell counts > 200 × 106/1 is safe and induces a transient increase in the absolute and percentage of CD4+ cell count without enhancing viral replication.

Original languageEnglish
Pages (from-to)55-60
Number of pages6
JournalJournal of Clinical Apheresis
Volume18
Issue number2
DOIs
Publication statusPublished - 2003

Fingerprint

Leukapheresis
CD4 Lymphocyte Count
HIV-1
Blood Cell Count
Viral Load
Immunization
Safety
Therapeutics

Keywords

  • CD4 cell counts
  • HIV-1 infection
  • Leukapheresis
  • Lymphocytes
  • Viral load

ASJC Scopus subject areas

  • Hematology

Cite this

Changes in immunological and virological parameters in HIV-1 infected subjects following leukapheresis. / Boulassel, M. R.; Spurll, G.; Rouleau, D.; Tremblay, C.; Edwardes, M.; Sekaly, R. P.; Lalonde, R.; Routy, Jean Pierre.

In: Journal of Clinical Apheresis, Vol. 18, No. 2, 2003, p. 55-60.

Research output: Contribution to journalArticle

Boulassel, MR, Spurll, G, Rouleau, D, Tremblay, C, Edwardes, M, Sekaly, RP, Lalonde, R & Routy, JP 2003, 'Changes in immunological and virological parameters in HIV-1 infected subjects following leukapheresis', Journal of Clinical Apheresis, vol. 18, no. 2, pp. 55-60. https://doi.org/10.1002/jca.10051
Boulassel, M. R. ; Spurll, G. ; Rouleau, D. ; Tremblay, C. ; Edwardes, M. ; Sekaly, R. P. ; Lalonde, R. ; Routy, Jean Pierre. / Changes in immunological and virological parameters in HIV-1 infected subjects following leukapheresis. In: Journal of Clinical Apheresis. 2003 ; Vol. 18, No. 2. pp. 55-60.
@article{f36c97dea57048a9801c0743d97aee0a,
title = "Changes in immunological and virological parameters in HIV-1 infected subjects following leukapheresis",
abstract = "In order to assess immune responses during HIV-1 therapeutic immunization, a large number of blood mononuclear cells (PBMC) are needed. Clinical tolerance and safety, as well as changes in immunological and virological parameters, were assessed, following leukapheresis in HIV-1 infected subjects with CD4+ cell count > 200 × 106/1. PBMC were collected using a Fenwal CS3000 cell separator in 29 subjects with mean CD4+ cell counts of 503 × 106/1 (range 172-1,119) and viral load of 2.5 log10 copies/ml (range < 1.7-5.4). Twenty-four (83{\%}) subjects were on antiretroviral therapy while 5 (17{\%}) were untreated. The blood volume processed was 7 L over a period of 3 hours. A mean value (± standard error) of 82 ± 26 × 109/1 lymphocytes was collected by a single apheresis in a mean volume of 200 ± 1.8 ml, containing 9.0 ± 1.3 × 109/1 CD4+ and 10.2 ± 1.3 × 109/1 CD8+ cells. The leukapheresis procedures were well tolerated and no immediate or delayed side effects were observed within 90 days of follow-up. No changes from blood pre-leukapheresis values were detected for white blood cells, lymphocytes, monocytes, CD8+, CD34+, naive and memory CD4+ cell counts immediately after, 1 h, 7 days, or within 90 days after leukapheresis. However, absolute CD4+ cell counts and percentage significantly increased from pre-leukapheresis values after 1 h (530 ± 43 vs. 700 ± 75 cell × 106/1; 32.6 ± 1.6 vs. 36.9 ± 1.9{\%}; P < 0.001 for both paired t-tests) before returning to pre-leukapheresis levels on day 7. No significant changes in viral load from pre-leukapheresis levels in treated or untreated subjects were detected at any time points. We conclude that leukapheresis in HIV-1 infected subjects with CD4+ cell counts > 200 × 106/1 is safe and induces a transient increase in the absolute and percentage of CD4+ cell count without enhancing viral replication.",
keywords = "CD4 cell counts, HIV-1 infection, Leukapheresis, Lymphocytes, Viral load",
author = "Boulassel, {M. R.} and G. Spurll and D. Rouleau and C. Tremblay and M. Edwardes and Sekaly, {R. P.} and R. Lalonde and Routy, {Jean Pierre}",
year = "2003",
doi = "10.1002/jca.10051",
language = "English",
volume = "18",
pages = "55--60",
journal = "Journal of Clinical Apheresis",
issn = "0733-2459",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Changes in immunological and virological parameters in HIV-1 infected subjects following leukapheresis

AU - Boulassel, M. R.

AU - Spurll, G.

AU - Rouleau, D.

AU - Tremblay, C.

AU - Edwardes, M.

AU - Sekaly, R. P.

AU - Lalonde, R.

AU - Routy, Jean Pierre

PY - 2003

Y1 - 2003

N2 - In order to assess immune responses during HIV-1 therapeutic immunization, a large number of blood mononuclear cells (PBMC) are needed. Clinical tolerance and safety, as well as changes in immunological and virological parameters, were assessed, following leukapheresis in HIV-1 infected subjects with CD4+ cell count > 200 × 106/1. PBMC were collected using a Fenwal CS3000 cell separator in 29 subjects with mean CD4+ cell counts of 503 × 106/1 (range 172-1,119) and viral load of 2.5 log10 copies/ml (range < 1.7-5.4). Twenty-four (83%) subjects were on antiretroviral therapy while 5 (17%) were untreated. The blood volume processed was 7 L over a period of 3 hours. A mean value (± standard error) of 82 ± 26 × 109/1 lymphocytes was collected by a single apheresis in a mean volume of 200 ± 1.8 ml, containing 9.0 ± 1.3 × 109/1 CD4+ and 10.2 ± 1.3 × 109/1 CD8+ cells. The leukapheresis procedures were well tolerated and no immediate or delayed side effects were observed within 90 days of follow-up. No changes from blood pre-leukapheresis values were detected for white blood cells, lymphocytes, monocytes, CD8+, CD34+, naive and memory CD4+ cell counts immediately after, 1 h, 7 days, or within 90 days after leukapheresis. However, absolute CD4+ cell counts and percentage significantly increased from pre-leukapheresis values after 1 h (530 ± 43 vs. 700 ± 75 cell × 106/1; 32.6 ± 1.6 vs. 36.9 ± 1.9%; P < 0.001 for both paired t-tests) before returning to pre-leukapheresis levels on day 7. No significant changes in viral load from pre-leukapheresis levels in treated or untreated subjects were detected at any time points. We conclude that leukapheresis in HIV-1 infected subjects with CD4+ cell counts > 200 × 106/1 is safe and induces a transient increase in the absolute and percentage of CD4+ cell count without enhancing viral replication.

AB - In order to assess immune responses during HIV-1 therapeutic immunization, a large number of blood mononuclear cells (PBMC) are needed. Clinical tolerance and safety, as well as changes in immunological and virological parameters, were assessed, following leukapheresis in HIV-1 infected subjects with CD4+ cell count > 200 × 106/1. PBMC were collected using a Fenwal CS3000 cell separator in 29 subjects with mean CD4+ cell counts of 503 × 106/1 (range 172-1,119) and viral load of 2.5 log10 copies/ml (range < 1.7-5.4). Twenty-four (83%) subjects were on antiretroviral therapy while 5 (17%) were untreated. The blood volume processed was 7 L over a period of 3 hours. A mean value (± standard error) of 82 ± 26 × 109/1 lymphocytes was collected by a single apheresis in a mean volume of 200 ± 1.8 ml, containing 9.0 ± 1.3 × 109/1 CD4+ and 10.2 ± 1.3 × 109/1 CD8+ cells. The leukapheresis procedures were well tolerated and no immediate or delayed side effects were observed within 90 days of follow-up. No changes from blood pre-leukapheresis values were detected for white blood cells, lymphocytes, monocytes, CD8+, CD34+, naive and memory CD4+ cell counts immediately after, 1 h, 7 days, or within 90 days after leukapheresis. However, absolute CD4+ cell counts and percentage significantly increased from pre-leukapheresis values after 1 h (530 ± 43 vs. 700 ± 75 cell × 106/1; 32.6 ± 1.6 vs. 36.9 ± 1.9%; P < 0.001 for both paired t-tests) before returning to pre-leukapheresis levels on day 7. No significant changes in viral load from pre-leukapheresis levels in treated or untreated subjects were detected at any time points. We conclude that leukapheresis in HIV-1 infected subjects with CD4+ cell counts > 200 × 106/1 is safe and induces a transient increase in the absolute and percentage of CD4+ cell count without enhancing viral replication.

KW - CD4 cell counts

KW - HIV-1 infection

KW - Leukapheresis

KW - Lymphocytes

KW - Viral load

UR - http://www.scopus.com/inward/record.url?scp=0041665088&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041665088&partnerID=8YFLogxK

U2 - 10.1002/jca.10051

DO - 10.1002/jca.10051

M3 - Article

C2 - 12874816

AN - SCOPUS:0041665088

VL - 18

SP - 55

EP - 60

JO - Journal of Clinical Apheresis

JF - Journal of Clinical Apheresis

SN - 0733-2459

IS - 2

ER -